tbuckley/cabot-search huggingface dataset:
Validation of Serum Aspergillus Galactomannan Index as a Surrogate Endpoint for Outcome of Invasive Aspergillosis: Clinical and Research Implications.
Authors: Gail Woods, Marisa Miceli, Monica Grazziutti, Somashekar Krishna, Nayyar Syed, Elias Kiwan, Mazhar Rahman, Bart Barlogie, Elias Anaissie
Journal: Blood (2006)
Rethinking the Ban — The U.S. Blood Supply and Men Who Have Sex with Men
Authors: Chana A. Sacks, Robert H. Goldstein, Rochelle P. Walensky
Journal: New England Journal of Medicine (2016)

The U.S. ban on blood donations from men who have sex with men was instituted at a time of great uncertainty, but advances in testing and in understanding of disease transmission offer better ways than a sweeping ban to minimize the risk of transfusion-related HIV.
Prevalence &amp; Prognosis Value of TET2 Gene Polymorphisms in Childhood Acute Myeloid Leukemia in Taiwan
Authors: Meng-Ju LI, Yung-Li Yang, Shiann-Tarng Jou, Meng-Yao Lu, Hsiu-Hao Chang, Kai-Hsin Lin, Dong-Tsamn Lin, Ching-Tien Peng
Journal: Blood (2011)
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)
Authors: Dan T. Vogl, Noopur S. Raje, Sundar Jagannath, Paul G. Richardson, Parameswaran Hari, Robert Z. Orlowski, Jeffrey Supko, David Tamang, Simon S Jones, Catherine Wheeler, Robert J Markelewicz, Sagar Lonial
Journal: Blood (2015)
Reduced Risk of Relapse In Pediatric ALL After Haploidentical Transplantation of T-Cell Depleted Grafts From KIR Haplotype B Donors,
Authors: Lena Oevermann, Sebastian Michaelis, Markus Mezger, Matthias Pfeiffer, Peter Lang, Tobias Feuchtinger, Rupert Handgretinger
Journal: Blood (2011)
Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.
Authors: Selami K. Toprak, Klara Dalva, Dilsa Mizrak, Mutlu Arat, Muhit Ozcan, Gunhan Gurman, Osman Ilhan, Meral Beksac
Journal: Blood (2004)
AB0686 Cross Sectional Cohort of Inflammatory Bowel Disease Related Arthritis in Rheumatology Secondary Care: Table 1.
Authors: H.D. Morrison, R. Sengupta, W. Tillett
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Joint involvement associated with inflammatory bowel disease (IBD) is well recognised within the concept of spondyloarthritis (SpA). There are two groups of articular manifestation in IBD: an axial arthropathy, including inflammatory back pain, sacroiliitis and ankylosing spondylitis (AS); and a lesser-studied peripheral arthritis, which is broadly divided into type 1 (oligoarthritis) and type 2 (polyarthritis). Previous data comes largely from cohorts of patients studied in gastroenterology secondary care, and identifies IBD related arthritis as a common and poorly understood condition. <h3>Objectives</h3> To describe the demographic characteristics, clinical features and current assessment and treatment of patients with Crohn9s Disease (CD) or Ulcerative Colitis (UC) related arthritis in rheumatology secondary care. <h3>Methods</h3> One hundred consecutive patients with a physician diagnosis of IBD related arthritis were selected for inclusion. Data was collected retrospectively from patient notes, hospital electronic records and imaging software. Demographic, patient reported, clinical and treatment data was collected. <h3>Results</h3> In this group of 100 patients, mean age 48.8 years (range 22–86), mean disease duration 7.8 years was an equal proportion of men (54) and women (46) and IBD subtype (CD=53, UC=41, Indeterminate=5, other=3). Disease phenotype and radiographic damage are described in table 1. At the last clinic assessment only 36% of patients had a tender and swollen joint count documented. The burden of peripheral symptoms was small with an average tender joint count of 1.43 (range 0–12) and swollen joint count of 0.67 (range 0–14). Frequency of axial and peripheral symptom assessment was similar at 72% and 75% respectively. Gut symptoms were only assessed in 50% of patients. 21% of patients had a documented history of uveitis and 22% a history of enthesitis. In patients with axial symptoms the mean outcome measures were as follows: BASDAI =4.4 (range 0.9–7.1), BASMI =3.7 (range 0–7.4) BASFI =4 (range 0–8.6), back pain =4 (range 0–9), patient global assessment =3.3 (range 1–9). 79% of patients had a current or prior treatment history with one or more disease modifying anti rheumatic drugs (DMARD), and 37% with anti-TNF therapy. At least 11% had a history of non-steroidal anti-inflammatory use. <h3>Conclusions</h3> We report data describing a distinct but heterogeneous clinical phenotype of IBD associated arthritis in rheumatology secondary care. We found high rates of DMARD and anti-TNF use, little erosive peripheral disease and variable clinical assessment. We suggest there is a need for improved assessment of IBD associated arthritis to better quantify the burden of disease and natural history. <h3>Disclosure of Interest</h3> None declared
Early Safety and Efficacy Analysis of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) for Elderly High Risk Patients with Untreated DLBCL.
Authors: Paul A. Hamlin, Craig H. Moskowitz, Brett C. Wegner, Carol S. Portlock, David J. Straus, Ariela Noy, Otilia Dumitrescu, Maria Lia Palomba, Steven M. Horwitz, Owen A. O’Connor, Neeta Pandit-Taskar, Chaitanya Divgi, Andrew D. Zelenetz
Journal: Blood (2005)
Role of Brain-Type Natriuretic Peptide and Cardiac Troponins as Predictors of Outcome in Multiple Myeloma
Authors: Ebru Koca, Gaurav Parikh, Ali Imran Amjad, Floralyn L Mendoza, Chitra M Hosing, Uday Popat, Richard E Champlin, Sergio Giralt, Muzaffar H. Qazilbash
Journal: Blood (2008)
PTU-100 A Regional Survey and Retrospective Study of The Risks of Tumour Implantation after Standard Pull-Through PEG Insertion for Head &amp; Neck Cancers – A Theoretical Risk?
Authors: M Swinton, DH Vasant, LD Morris, T Earley, Y Clarkson, PL Shields, EJ Nixon
Journal: Gut (2016)

<h3>Introduction</h3> Despite documented low risk (&lt;1%) of stomal metastases and limited evidence-base, current BSG guidelines advocate a direct puncture approach to gastrostomy in head &amp; neck cancers (HNC).<sup>1</sup> We hypothesised that there would be a variation in the gastrostomy insertion practices for HNC and surveyed hospitals in our region and aimed to retrospectively determine the incidence of PEG site metastases at our centre where pull-through technique PEG is often the first line approach in HNC. <h3>Methods</h3> Firstly, an electronic survey on gastrostomy insertion practices in HNC was circulated to all members of the regional Gastroenterology network (representing 11 NHS hospital trusts in the North West of England). Secondly, in a retrospective study, all PEG placements using pull-through technique for HNC at Lancashire Teaching Hospitals between 2011–2014 were reviewed. Data including patient demographics, tumour site, size, stage and histology, HNC treatments before and after PEG, PEG insertion details, length of follow-up, imaging of the PEG site post procedure and sites of recurrence, were recorded. Data are expressed as the mean (± standard error of the mean) unless stated otherwise. <h3>Results</h3> The survey of endoscopists (n = 30, 11 consultants) from ten NHS trusts in the North West revealed that seven centres were compliant with BSG guidance (six using radiologically inserted gastrostomy techniques and one offering endoscopic gastropexy as first-line). Three centres use the pull-through technique for HNC. Only 2/30 (7%) of respondents (both consultants) have ever encountered a case of PEG site metastases in their careers post pull-through PEG insertion for HNC. In the retrospective study, 106 HNC patients (age 60 ± 1 years, 77 male, 29 female) were followed-up for 784 ± 40 days post pull-through PEG insertion. Most patients had tumours within the oral cavity (70%), 22% had tumours in the pharynx or below, with the remainder having neck lesions. Overall, in 92% of cases PEG placements were prophylactic (pre-treatment), 49% had documented peg removal at a mean time of 499 ± 45 days, 29% developed recurrent/ metastatic disease and 25% died at 488 ±54 days post PEG insertion. There were no cases of PEG site metastases identified, however only 36% had imaging of the PEG site post-procedure with most recent imaging available at 682 ± 102 days post-procedure. <h3>Conclusion</h3> Our survey highlights a variation in gastrostomy practices for HNC across the region. Despite the BSG guidelines, some centres still use the pull-through approach and our data suggest the risk of seeding with this approach is low. <h3>Reference</h3> 1 Westaby D, <i>et al</i>. <i>Gut</i> 2010;<b>59</b>(12):1592–605. <h3>Disclosure of Interest</h3> None Declared
Acute Promyelocytic Leukemia Harboring STAT5b-RARα Fusion Gene and G596V Mutation in the Stat5b SH2 Domain of the Fusion Gene.
Authors: Eisaku Iwanaga, Miki Nakamura, Tomoko Nanri, Toshiro Kawakita, Naofumi Matsuno, Koyu Hoshino, Kentaro Horikawa, Hiroaki Mitsuya, Norio Asou
Journal: Blood (2007)
FRI0106 The Association of Fatigue, Comorbidities and Anti Rheumatic Drugs in Rheumatoid Arthritis: Results from The Comedra Study
Authors: A. Tournadre, B. Pereira, L. Gossec, M. Soubrier, M. Dougados
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The mechanisms of fatigue in rheumatoid arthritis (RA) are still unclear and the effect of antirheumatic drugs on fatigue not fully established. <h3>Objectives</h3> To analyse in a large cohort of RA the factors associated with fatigue focusing on social aspects, comorbidities and treatment intake. <h3>Methods</h3> Cross sectional analyses were performed on RA patients from the French cohort study of comorbidities COMEDRA (1). Fatigue was assessed as a quantitative variable (RAID3 0–10 numeric scale) or by class (acceptable &lt;3; moderate 3–4; severe ≥5 out of 10). Relationship with demographic, social, disease characteristics, treatments, comorbidities, physical activity, quality of life was investigated in univariate analyses (Table) and multivariate polynomial regression (Figure). <h3>Results</h3> 962 patients were analysed (age 57.7 ± 11.1 years, disease duration 11.1 years [6.2–19.1], mean DAS28 3.1 ± 1.3), 763 (79%) were female. The mean fatigue score was 3.8± 2.7. Severe fatigue was more frequent in women, in patients not working, with less physical activity and more obesity. Fatigue was correlated with disease duration (p=0.05), all disease activity index (p&lt;0.001), pain (p&lt;0.001), mHAQ (p&lt;0.001), sleep (p&lt;0.001) and emotional well-being (p&lt;0.001). Among comorbidities, hypertension, chronic obstructive pulmonary disease (COPD), fracture history and RA-related surgery were associated with fatigue. Fatigue was more severe in patients with current NSAID, steroid, biologic treatments. Methotrexate use and the type of biologic did not impact fatigue score. <h3>Conclusions</h3> Beyond the expected association of fatigue with disease activity, female gender, pain, sleep and emotional well-being, comorbidities and less physical activity could contribute to the frequent fatigue noted in RA. Fatigue was associated with steroids, NSAIDs, biotherapies but not with methotrexate and did not depend of the type of biotherapy. <h3>References</h3> Dougados M et al. Ann Rheum Dis. 2015;74(9):1725–33 <h3>Disclosure of Interest</h3> None declared
Dose-Dependent Antithrombotic Effects of Apixaban, an Oral Direct Factor Xa Inhibitor, in Prevention and Treatment of Thrombosis in Rabbit Models of Arteriovenous-Shunt and Venous Thrombosis at Doses That Preserve Hemostasis.
Authors: Pancras C. Wong, Earl J. Crain, Donald J. Pinto, Carol A. Watson
Journal: Blood (2007)
THU0387 Serum Levels of TNF Alpha and VEGF as Markers of Disease Activity in Patients with Axial Spondyloarthritis
Authors: B. Mahendran, R. Sankalingam, K. Mohanasundaram, S. Sankaran, M. Mani, B. Chilukuri
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Monitoring of disease activity in axial spondyloarthritis is difficult due to lack of specific markers of inflammation. Conventional markers of inflammation namely ESR and CRP, seldom correlates with disease activity. To help in the early diagnosis and monitoring of axial spondyloarthritis, there has been a growing need for new biomarkers of disease activity. <h3>Objectives</h3> To investigate the role of serum vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF α) as markers of disease activity in patients with Axial Spondyloarthritis (axSpA). <h3>Methods</h3> 40 patients with axSpA (28 with Ankylosing Spondylitis and 12 with non-radiological axSpA; mean age 29 years, mean duration 5 months) were included in this study. ESR, CRP, BASDAI/BASFI, serum TNF α and VEGF levels were assessed at baseline and after 12 weeks of therapy with either etanercept or NSAIDs (20 patients in each group). 20 healthy age and sex matched controls were also recruited for the study. <h3>Results</h3> Patients with axSpA had higher levels of serum TNF α (mean 341pg/ml) and VEGF (mean 797pg/ml) when compared with healthy controls (mean 72.5 pg/ml, p&lt;0.001 and mean 269 pg/ml, p&lt;0.001). There was significant reduction in serum TNF α and VEGF levels after 12 weeks of treatment with etanercept (mean 161pg/ml, p&lt;0.001 and mean 442 pg/ml, p&lt;0.001 respectively) but not with NSAID (p=0.29, p=0.25). Both TNF α and VEGF had a positive correlation with BASDAI (r=0.57, p&lt;0.01 and r=0.44, p&lt;0.01) and BASFI (r=0.61, p&lt;0.01 and r=0.33, p=0.03) at baseline. The levels of TNF α and VEGF showed no correlation with ESR and CRP (p=0.48, p=0.07 and p=0.21, p=0.06 respectively)at baseline. There was no correlation between BASDAI and levels of ESR, CRP (p=0.27 and p=0.49 respectively). <h3>Conclusions</h3> Serum levels of TNF α and VEGF serve as better markers of disease activity when compared with ESR and CRP in axSpA. Significant reduction in VEGF levels with treatment makes it a potentially new therapeutic target in axSpA <h3>References</h3> Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis. 2014 Dec;73(12):2137–43 Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis. 2011 Aug;70(8):1375–81 <h3>Disclosure of Interest</h3> None declared
Potent Graft-Versus-Renal Cell Carcinoma (RCC) Effects in a Murine Minor Histocompatibility Antigen (mHa)-Mismatched Allogeneic Transplant Model.
Authors: Andreas Lundqvist, Ramaprasad Srinivasan, Dante Suffredini, Yoshiyuki Takahashi, Jason Wynberg, Takehito Igarashi, Amy Reese, Warren Shlomchik, Richard Childs
Journal: Blood (2004)
Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes
Authors: Virginie Chesnais, Marie-Laure Arcangeli, Caroline Delette, Alice Rousseau, Hélène Guermouche, Carine Lefevre, Sabrina Bondu, M’boyba Diop, Meyling Cheok, Nicolas Chapuis, Laurence Legros, Sophie Raynaud, Lise Willems, Didier Bouscary, Evelyne Lauret, Olivier A. Bernard, Olivier Kosmider, Françoise Pflumio, Michaela Fontenay
Journal: Blood (2016)
THU0120 Long Term Safety and Efficacy of Biosimilar Infliximab among Patients with Inflammatory Arthritis Switched from Reference Product: Table 1.
Authors: A. Abdalla, N.E. Byrne, R. Conway, T. Walsh, G. Mannion, M. Hanly, M. O'Sullivan, A. Curran, J.J. Carey
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Biologic medications are effective treatments for inflammatory arthritis, however they are expensive, costing around €15,000 per patient per year, or 5% of the annual healthcare budget in Ireland. Measures to reduce this cost without sacrificing efficacy or safety are important. Studies switching patients to cheaper approved biosimilar products are few. <h3>Objectives</h3> To evaluate the efficacy and safety of biosimilar Infliximab in adult patients with inflammatory arthritis switched from reference product in our centre. <h3>Methods</h3> In April 2014 all patients attending our rheumatology service for Infliximab infusions were switched from reference product to a biosimilar infliximab following verbal consent and hospital approval. Our local I.R.B. approved a retrospective review of these patients following requests from other centres for information on our experience. <h3>Results</h3> 34 patients with inflammatory arthritis were switched from reference product Infliximab in 2014: 50% female, mean (SD) age 55 years (12.9), mean disease duration 14.8 years (9.7), mean duration on infliximab 70 months (59.6) and two thirds were taking oral DMARDs. There was no difference in efficacy or safety in the first 6 months of therapy. By the end of 2015, the mean follow-up on biosimilar infliximab was 15.8 months (6.3). Our results show no significant difference in HAQ score, patient global assessment of disease activity, number of disease flares or medication dose between the originator and the biosimilar Infliximab. However reported pain and CRP values were significantly higher during the longer follow-up period (<i>p</i> value 0.028, 0.001 respectively). There was no significant difference in the number of adverse events or infusion reactions during similar follow-up periods, or the number of patients who discontinued therapy (3 Vs 5). 1 frail patient with multiple co-morbidities died during follow-up. Substantial savings were obtained by using the biosimilar product. <h3>Conclusions</h3> Our patients experienced similar efficacy and safety for managing their arthritis with biosimilar infliximab as reference product Infliximab, but at a much lower cost. <h3>Acknowledgement</h3> National University of Ireland, Galway for statistical software support. <h3>Disclosure of Interest</h3> A. Abdalla: None declared, N. Byrne: None declared, R. Conway: None declared, T. Walsh: None declared, G. Mannion: None declared, M. Hanly: None declared, M. O9Sullivan: None declared, A. Curran: None declared, J. Carey Consultant for: Consulting fees and speaker fees by MSD Ireland and Hospira and received travel support and grants from MSD Ireland and Centrecor,USA
OP0186 Immune Complex Bound U1 and Y1 RNA Correlates with Interferon-Stimulated Gene Expression and Disease Activity: An Observational Study of Sysytemic Lupus Erythematosus Patients
Authors: J. Doedens, W. Jones, K. Hill, M. Mason, P. Linsley, P. Mease, M. Dall'Era, C. Aranow, R. Martin, S. Cohen, R. Fleischmann, A. Kivitz, D. Burge, D. Chaussabel, K. Elkon, J. Posada, C. Gabel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Immune complexes (ICs) containing RNA are thought to play a central role in driving interferon (IFN) production and systemic inflammation in systemic lupus erythematosus (SLE) via activation of intracellular Toll-Like Receptors (TLRs). However, quantitation of IC-bound RNAs in SLE patient plasma has not previously been performed. <h3>Objectives</h3> To quantify IC-associated U1 and Y1 RNA and relate the findings to the interferon (IFN) signature and SLE clinical activity. <h3>Methods</h3> Medications and SLEDAI measurements were completed on 228 SLE patients. Autoantibodies were quantified by a Bioplex assay. Peripheral blood transcript profiles for 186 selected genes were quantified by a dynamic array QPCR analysis. ICs were isolated from plasma by protein A bead capture and associated RNA quantified by QPCR using primer/probes designed to detect small, noncoding U1 and Y1 RNA transcripts. <h3>Results</h3> The autoantibodies anti-SmRNP and anti-Ro60 displayed the strongest associations with IC-bound U1 and Y1 RNA levels, respectively. When patients were grouped into 4 categories based on the presence of ICs containing U1 and/or Y1 RNA, blood gene expression changes in the U1-/ Y1- group were significantly lower than observed in the three groups possessing U1 alone, Y1 alone, or both RNA molecules. Within the U1 RNA-positive groups, the top 10 up-regulated genes were increased 10–48 fold compared to healthy volunteers (associated p values exceeding 10<sup>–15</sup>) and corresponded to known IFN-inducible transcripts. IC-bound U1 and Y1 RNA levels showed significant correlations with each other and also with disease activity (SLEDAI) (p&lt;0.0003). <h3>Conclusions</h3> The enhanced expression of IFN-inducible transcripts in blood from patients possessing IC-bound U1 and/or Y1 RNA lends further support to the hypothesis that these RNA molecules are involved in triggering TLR7 and stimulating interferon production in SLE patients. Therapeutic strategies that seek to reduce the quantities of RNA associated with ICs may be an attractive approach to blocking downstream IFN production and immune system activation. <h3>Disclosure of Interest</h3> None declared